US Bancorp DE Has $11.40 Million Stake in Relx Plc $RELX

Key Points

• US Bancorp DE reduced its stake in Relx Plc by 13.4% in the second quarter, holding 209,782 shares valued at $11.4 million after selling 32,587 shares.
• Relx's share price has dropped 0.8% to $44.80, with a market cap of $81.87 billion and a recent downgrade from analysts, although the consensus rating remains a "Buy."
• Relx Plc announced a semi-annual dividend of $0.2634 per share, representing a yield of 170.0%, and has a dividend payout ratio (DPR) of 28.49%.

US Bancorp DE trimmed its position in shares of Relx Plc (NYSE:RELX - Free Report) by 13.4% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 209,782 shares of the technology company's stock after selling 32,587 shares during the period. US Bancorp DE's holdings in Relx were worth $11,400,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of RELX. Larson Financial Group LLC grew its stake in Relx by 612.5% during the first quarter. Larson Financial Group LLC now owns 513 shares of the technology company's stock worth $26,000 after buying an additional 441 shares in the last quarter. WPG Advisers LLC acquired a new stake in Relx during the first quarter worth about $28,000. Golden State Wealth Management LLC grew its stake in Relx by 100.0% during the first quarter. Golden State Wealth Management LLC now owns 588 shares of the technology company's stock worth $30,000 after buying an additional 294 shares in the last quarter. Cornerstone Planning Group LLC grew its stake in Relx by 325.2% during the first quarter. Cornerstone Planning Group LLC now owns 693 shares of the technology company's stock worth $37,000 after buying an additional 530 shares in the last quarter. Finally, Ameritas Advisory Services LLC acquired a new stake in Relx during the second quarter worth about $64,000. 15.02% of the stock is currently owned by institutional investors and hedge funds.

Relx Stock Down 0.8%

Shares of NYSE RELX opened at $44.80 on Friday. The company has a 50 day simple moving average of $47.22 and a 200 day simple moving average of $50.81. The firm has a market cap of $81.87 billion, a PE ratio of 24.08, a price-to-earnings-growth ratio of 2.92 and a beta of 0.87. Relx Plc has a 1 year low of $44.19 and a 1 year high of $56.33. The company has a debt-to-equity ratio of 2.55, a current ratio of 0.47 and a quick ratio of 0.42.

Relx Cuts Dividend

The firm also recently disclosed a semi-annual dividend, which was paid on Tuesday, September 16th. Investors of record on Friday, August 8th were issued a $0.2634 dividend. This represents a yield of 170.0%. The ex-dividend date was Friday, August 8th. Relx's dividend payout ratio (DPR) is 28.49%.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the stock. Wall Street Zen downgraded shares of Relx from a "buy" rating to a "hold" rating in a research note on Friday, September 5th. Weiss Ratings restated a "buy (b)" rating on shares of Relx in a research note on Wednesday. Morgan Stanley restated an "overweight" rating on shares of Relx in a research note on Thursday, September 11th. Kepler Capital Markets upgraded shares of Relx from a "hold" rating to a "strong-buy" rating in a research note on Thursday, September 18th. Finally, Barclays restated an "overweight" rating on shares of Relx in a research note on Tuesday. One investment analyst has rated the stock with a Strong Buy rating and five have assigned a Buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Buy".

About Relx

RELX Plc engages in provision of information and analytics solutions for professional and business customers across industries. It operates through the following business segments: Scientific, Technical & Medical; Risk & Business Analytics; Legal; and Exhibitions. The Scientific, Technical & Medical segment is a global information analytics business that helps institutions and professionals advance healthcare, open science, and improve performance for the benefit of humanity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.